Creatine shows promise in boosting cancer immune response
This digest was compiled by AI from multiple sources — links to the originals are below.
A study by UCLA researchers suggests creatine, a popular sports supplement, may help the immune system recognize and attack cancer tumors. The research found that creatine enhances the function of dendritic cells, which activate T-cells to destroy cancer cells. In mice with melanoma, daily creatine administration was linked to slower tumor growth.
The Mechanism
UCLA researchers led by professor Lily Yang found that dendritic cells require creatine for normal function. When cells lost the ability to absorb creatine, they survived poorly, activated weakly, and presented tumor antigens less effectively to T-cells. Adding creatine boosted dendritic cell activity, increasing signaling molecules and T-cell activation.
Preclinical Evidence
In mouse models of melanoma, daily creatine administration was associated with slower tumor growth and higher numbers of active dendritic cells. The study suggests creatine could complement existing immunotherapies by targeting an earlier stage of immune defense — dendritic cell activation — rather than focusing solely on T-cells.
Caveats and Limitations
The study does not prove that creatine can treat or prevent cancer in humans. Safety, efficacy, and optimal doses for cancer patients have not been tested in clinical trials. Some preclinical studies have linked creatine to increased metastasis in certain tumor models, so experts caution against using it as a cancer treatment until large clinical trials are conducted.
What's Next
The UCLA team plans further preclinical studies to explore creatine's potential in combination with existing immunotherapies. It remains unclear whether human trials will confirm the findings or reveal safety concerns that could limit clinical application.
1 source
Creatine shows promise in boosting cancer immune response
